In the landscape of sexual health pharmacology, the vast majority of research over the past three decades has focused on vascular mechanics—specifically, increasing blood flow via PDE5 inhibitors. However, the development of PT-141 (Bremelanotide) represents a fundamental paradigm shift. Rather than targeting the peripheral vascular system, PT-141 targets the central nervous system, directly modulating the […]
